1. Home
  2. PRFX vs AIDX Comparison

PRFX vs AIDX Comparison

Compare PRFX & AIDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PainReform Ltd.

PRFX

PainReform Ltd.

N/A

Current Price

$0.63

Market Cap

2.6M

Sector

Health Care

ML Signal

N/A

Logo 20/20 Biolabs Inc. Common Stock

AIDX

20/20 Biolabs Inc. Common Stock

N/A

Current Price

$0.18

Market Cap

2.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PRFX
AIDX
Founded
2007
2000
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Precision Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6M
2.9M
IPO Year
2020
2025

Fundamental Metrics

Financial Performance
Metric
PRFX
AIDX
Price
$0.63
$0.18
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
55.4K
★ 206.0K
Earning Date
09-03-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 34.48
EPS
★ N/A
N/A
Revenue
N/A
★ $2,045,133.00
Revenue This Year
N/A
$44.20
Revenue Next Year
N/A
$95.73
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 16.71
52 Week Low
$0.58
$0.18
52 Week High
$5.39
$18.96

Technical Indicators

Market Signals
Indicator
PRFX
AIDX
Relative Strength Index (RSI) 34.85 30.30
Support Level N/A N/A
Resistance Level $1.25 $0.27
Average True Range (ATR) 0.10 0.03
MACD -0.01 0.00
Stochastic Oscillator 5.62 0.00

Price Performance

Historical Comparison
PRFX
AIDX

About PRFX PainReform Ltd.

PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasize reformulation and sustained-release drug-delivery technologies and AI-driven energy analytics. PRF-110, the company's lead product, is based on the local anesthetic ropivacaine and targets the postoperative pain relief market. The company has two operating segments composed of the Clinical Development segment, which facilitates the development of potential new drug compounds, and the Solar segment, which comprises the design and development of the company's intellectual property and the sale related service offerings.

About AIDX 20/20 Biolabs Inc. Common Stock

20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.

Share on Social Networks: